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Synergistic action of phage phiIPLA-RODI and lytic protein
CHAPSH3b: a combination strategy to target Staphylococcus
aureus biofilms
Ana Catarina Duarte1,2, Lucía Fernández 1,2✉, Vincent De Maesschalck 3,4, Diana Gutiérrez3, Ana Belén Campelo1, Yves Briers3,
Rob Lavigne4, Ana Rodríguez 1,2 and Pilar García1,2
Staphylococcus aureus is considered a priority pathogen due to its increasing acquisition of antibiotic resistance determinants.
Additionally, this microbe has the ability to form recalcitrant biofilms on different biotic and inert surfaces. In this context,
bacteriophages and their derived lytic proteins may be a forward-looking strategy to help combat staphylococcal biofilms.
However, these antimicrobials exhibit individual limitations that may be overcome by combining them with other compounds. This
work investigates the combination of a phage-derived lytic protein, CHAPSH3b, and the virulent bacteriophage phiIPLA-RODI. The
obtained results show the synergy between both antimicrobials for the treatment of 24-h-old S. aureus biofilms, with greater
reductions in viable cell counts observed when phage and lysin are applied together compared to the individual treatments. Time-
kill curves and confocal microscopy revealed that the fast antibacterial action of CHAPSH3b reduces the population up to 7 hours
after initial exposure, which is subsequently followed by phage predation, limiting regrowth of the bacterial population. Moreover,
at least 90% of bacteriophage insensitive mutants are susceptible to the lytic protein. Therefore, CHAPSH3b might help curtail the
development of phage resistance during treatment. The combination of the lysin and phiIPLA-RODI also showed promising results
in an ex vivo pig skin model of wound infection. Overall, the results of this study demonstrate that the combination of phage-
derived lytic proteins and bacteriophages can be a viable strategy to develop improved antibiofilm products.
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INTRODUCTION
Staphylococcus aureus is a Gram-positive human opportunistic
pathogen responsible for multiple infections1,2, including food
poisoning due to the secretion of heat-stable enterotoxins3,4.
Indeed, this microbe is armed with an arsenal of virulence factors,
including numerous toxins, immune evasion factors, and mole-
cules involved in biofilm development3.
Biofilm formation is a complex process involving the initial
adherence of bacterial cells to a surface, followed by the
production of an extracellular matrix5–7. Importantly, biofilm-
embedded cells are known for their increased ability to withstand
antibiotics and disinfectants compared to planktonic cells8. This
makes biofilms the perfect reservoir for pathogenic bacteria on
surfaces of clinical and industrial settings. As such, biofilm
formation by this pathogen simultaneously favors persistent
infection, antibiotic resistance, and immune evasion9. Moreover,
biofilms are considered to be involved in at least 65% of all
infections in humans10,11. In S. aureus, one of the major matrix
components is polysaccharide intercellular adhesin (PIA)/poly-N-
acetyl-1,6-b-glucosamine (PNAG), which is synthesized by the
proteins encoded by the intercellular adhesion (ica) operon12 and
provides structural integrity to the biofilms. However, some
surface proteins, such as protein A13 or the biofilm-associated
protein (Bap)14,15, as well as extracellular DNA (eDNA) also
contribute to biofilm matrix development and stabilization5.
Antimicrobial resistance has become a major medical threat
worldwide and, in this context, S. aureus is currently considered a
priority pathogen. For example, the World Health Organization
(WHO) has estimated that 60% of all reported S. aureus infections
in Europe are caused by methicillin-resistant strains (MRSA)16. Also,
resistance to vancomycin, the antibiotic of choice to treat MRSA
infections, can be a cause of concern17. More recently, the
lipopeptide daptomycin was introduced for the treatment of
complicated staphylococcal infections, but resistant strains have
also been isolated since then18.
In this scenario, bacteriophages (phages) and their derived
proteins have been proposed as an alternative or complementary
strategy to conventional therapeutics that may help to control the
spread of antibiotic resistance in bacterial pathogens. One of the
advantages of bacteriophages is their specificity against one
bacterial genus or species, being innocuous against non-target
bacteria. Moreover, phages are the most abundant biological
entities on earth, multiply themselves naturally, and are safe for
humans19,20. Typically, phages degrade the structural peptidogly-
can present in the bacterial cell wall using two classes of lytic
proteins: virion-associated peptidoglycan hydrolases (VAPGHs)
degrade peptidoglycan in the initial steps of the infection, and
endolysins help release the phage progeny during the late phase
of the lytic cycle21–24. The modular structure of lytic proteins
facilitates the design of new chimeric proteins via domain
shuffling, which frequently displays improved lytic activity22,25,26
and overall enhanced traits27. These enzymes can be used as
antibacterial agents targeting bacteria from the outside, accessing
the peptidoglycan, and destroying the cell walls28–30. Furthermore,
the rate of selection of bacterial resistance to lysins is very low31
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and, while still being quite specific, their spectrum of action
generally exceeds that of bacteriophages. For all these reasons,
phage lytic proteins constitute promising antimicrobial
candidates.
Nevertheless, there are some disadvantages associated with the
therapeutic use of both phages and phage-derived proteins. In the
case of phages, it is common to observe the selection of
bacteriophage insensitive mutants (BIMs) during therapy32,
together with their narrow host range33, and their potential
contribution to horizontal gene transfer34. Similarly, there are also
concerns associated with the use of phage lytic proteins. For
instance, unlike phages, the concentration of these proteins
decreases gradually after administration, as is also the case for
standard-of-care antibiotics. Furthermore, it is important to ensure
protein stability under the desired environmental conditions to
avoid protein inactivation by factors like pH, temperature, or
degradation by proteases amongst others35.
One way to overcome the individual shortcomings of bacter-
iophages or lysins is by combining them with other antimicrobial
agents. Indeed, several studies have demonstrated that the
combination of phages with antibiotics or antiseptics is promising,
exhibiting a synergistic effect in biofilm removal experiments36–38.
Another strategy is the combination of multiple phages targeting
different receptors in a single phage preparation, known as a
phage cocktail39,40. Phage lytic enzymes have also been combined
with other antimicrobials like antibiotics41–43 or used as part of a
multi-enzyme approach by mixing them with depolymerases,
which target polysaccharides such as those present in the
extracellular matrix of biofilms44. However, to our knowledge, no
study has found synergistic effects between phages and lytic
proteins.
In our previous work, we showed that chimeric protein
CHAPSH3b, which consists of the CHAP domain from peptidogly-
can hydrolase HydH5 and the SH3b cell wall binding domain
(CBD) from lysostaphin45, displays antistaphylococcal activity in
growth medium and milk, as well as biofilm-removal proper-
ties45,46. Furthermore, CHAPSH3b inhibits S. aureus biofilm
formation, presumably by the downregulation of autolysin-
encoding genes46. Moreover, we have characterized the virulent
phage vB_SauM_phiIPLA-RODI (phiIPLA-RODI), which is also
effective in eliminating staphylococcal biofilms39. This study
aimed to assess the potential interactions between phage
phiIPLA-RODI and the phage-derived chimeric lytic protein
CHAPSH3b when used together for biofilm removal.
RESULTS
Phage phiIPLA-RODI and chimeric lysin CHAPSH3b act
synergistically to remove staphylococcal biofilms
To examine the potential interactions between phage phiIPLA-
RODI and the lytic protein CHAPSH3b for biofilm removal, three S.
aureus strains were chosen on the basis of their biofilm formation
ability and matrix composition. These strains include S. aureus
V329 and 15981, which have a strong biofilm production
phenotype, and S. aureus IPLA1, a weak biofilm producer15,47.
Regarding their matrix composition, S. aureus V329 biofilm is
mostly composed of Bap (biofilm-associated protein) and eDNA,
whereas both S. aureus 15981 and IPLA1 biofilms mainly consist of
exopolysaccharides47.
First, the susceptibility of the three strains to phiIPLA-RODI and
CHAPSH3b was determined by performing minimum inhibitory
concentration (MIC) assays. The MIC values of the chimeric protein
were quite similar for all three strains. Indeed, S. aureus IPLA1 and
V329 strains showed identical susceptibility with a MIC of 60.5 µg/
ml (~2 µM), whereas strain S. aureus 15981 had a higher MIC of
121.05 µg/ml (~4 µM). For phage phiIPLA-RODI, strain S. aureus
IPLA1 was the most susceptible, with a MIC of 103 PFU/ml,
followed by S. aureus V329 with a MIC of 109 PFU/ml and, finally, S.
aureus 15981, with a MIC over 109 PFU/ml. In addition, the
efficiency of plating (EOP) of phiIPLA-RODI on strains IPLA1, 15981,
and V329 were 1.0 ± 0.00, 0.80 ± 0.02, and 0.55 ± 0.19, respectively.
In turn, the adsorption rates on strains IPLA1, 15981, and V329
were not significantly different from each other (83.77 ± 2.41,
85.34 ± 14.37, and 79.97 ± 6.53%, respectively).
Next, to establish the antibiofilm potential of these phage-
derived antimicrobials, 24-h biofilms of the three strains were
treated with different combinations of the phage at 1010 PFU/ml
and the chimeric protein at 4 or 8 µM. The results indicated a
potential synergy between phiIPLA-RODI and CHAPSH3b (Fig. 1).
Treatment of biofilms formed by S. aureus 15981 with the phage
or the protein alone did not significantly affect the number of
viable cells compared to the untreated control (Fig. 1a).
Conversely, the combination of both antimicrobials did lead to a
significant reduction in viable cells of 1.4 (p= 0.0498) and 1.9 log
units (p= 0.0152) at protein concentrations of 4 and 8 µM,
respectively (Fig. 1a). These results suggested a synergistic effect
between phage and protein at 8 µM with an interaction index of
0.55. Interestingly, the interaction between the phage and the
protein at 4 µM was additive with an interaction index of −0.45.
Regarding total biomass, the addition of the phage alone or the
protein at 4 µM did not have any significant impact, whereas
treatment with CHAPSH3b at 8 µM resulted in a significant
biomass reduction (p= 0.0076) (Fig. 1b). The combination
treatment always led to a decrease in total attached biomass
(Fig. 1b). In S. aureus IPLA1 biofilms, there was a significant
reduction in viable cells when applying the bacteriophage
individually (0.5 log units) (p= 0.0284) or in combination with
both concentrations of the protein (2.1 (p= 0.0239) and 2.2 log
units (p= 0.0039) corresponding to 4 and 8 µM of CHAPSH3b,
respectively), but not with CHAPSH3b alone (Fig. 1c). Thus, the
combination of the phage with the chimeric protein at 4 and 8 µM
had a synergistic effect with interaction index values of 1.10 and
1.27, respectively. Moreover, a significant reduction in total
biomass was observed when using the phage alone (p= 0.035)
or combined with 8 µM CHAPSH3b (p= 0.011) (Fig. 1d). Finally, in
the case of strain S. aureus V329, a significant reduction in both
viable cell counts (Fig. 1e) and biomass (Fig. 1f) was observed
when combining the phage with the protein at different
concentrations. Thus, a reduction of 0.9 log units (p= 0.0059)
was observed when the biofilm was treated with the protein alone
(4 µM), whereas a combination of the phage and the protein at 4
and 8 µM led to decreases of 2.1 (p= 0.0016) and 2.2 (p= 0.0013)
log units, respectively. These results indicate that there was a
synergistic effect in both cases, with interaction index values of
0.95 and 1.46 for 4 and 8 µM CHAPSH3b, respectively. Regarding
total biomass, the protein alone or in combination with the phage
significantly reduced the biofilm (p-values between
< 0.0001 and 0.0002). Of note, the reduction in total biomass
was higher in V329 than in the other two strains tested.
Based on these results, the S. aureus strain V329 and a protein
concentration of 8 µM were selected for further experiments to
examine these synergistic interactions more closely, since these
conditions exhibited the highest interaction index. To better
understand the effect of the combination treatment on biofilm
structure, 24-h-old biofilms were treated with only protein or
combined with the phage and compared to an untreated control
by visualization with confocal microscopy (CLSM). After 24 h of
incubation without treatment, strain S. aureus V329 displayed
thick, well-structured biofilms (Fig. 2a and e). However, biofilm
thickness was notably reduced after treatment with the protein
alone (Fig. 2b and f). In contrast, treatment with the phage alone
did not lead to any major change compared to the untreated
control (Fig. 2c and g). However, the combination treatment had
an even larger and more extensive impact than the protein alone
(Fig. 2d and h). In addition, the latter biofilm contained a higher
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number of dead or compromised cells, which appeared red due to
staining with propidium iodide (Fig. 2d and h).
Phage predation curtails regrowth of the microbial population
after CHAPSH3b inactivation
To study the killing dynamics of the combination therapy using
phage phiIPLA-RODI and the chimeric protein CHAPSH3b, 24-h-
old biofilms of strain S. aureus V329 were treated with a
combination of phage (109 PFU/ml) and protein (8 µM) or the
two antimicrobials independently. CHAPSH3b exhibited a notable
disrupting activity against the biofilm after just 3 h of treatment,
judging by the reduction (0.7 log units) in attached bacterial
counts (Fig. 3). Viable cell counts further decreased after 5 h of
treatment (1.4 log units), and the maximum reduction (2.5 log
units) was achieved after 7 h (Fig. 3). However, regrowth of the
bacterial population was observed after 24 h of incubation at
37 °C, reaching viable cell counts similar to those of the untreated
control. In contrast to the lytic protein, phage phiIPLA-RODI was
not efficient in killing the bacterial cells attached to the surface at
any time point. In spite of this, the phage did have an impact
when combined with CHAPSH3b, demonstrating to be even more
effective for biofilm removal than the protein alone. Thus,
reductions in viable cell counts of 1.4 log units, 2.8 log units, and
2.8 log units were, respectively, observed after 3 h, 5 h, and 7 h of
treatment. However, the most remarkable difference with the
Fig. 1 Treatment of preformed biofilms formed by different S. aureus strains. Biofilms formed by S. aureus 15981 (a and b), IPLA1 (c and d),
and V329 (e and f) were treated with bacteriophage phiIPLA-RODI (1010 PFU/ml) (white bars), chimeric protein CHAPSH3b (4 and 8 µM) (light
gray and dark gray bars, respectively) or the combination of both antimicrobials (striped and dotted bars). Biofilms were allowed to develop
for 24 h and then treated for another 24 h at 37 °C. TSB medium alone was added to the control wells (black bars). After incubation, the viable
cell counts of the three strains were determined (a, c and e) and the adhered biomass was quantified (A595) by crystal violet staining (b, d, and
f). Data represent the means ± standard deviations of three independent experiments. Bars with an asterisk are statistically different from the
untreated control, and bars with a hash sign are statistically different from the treatment with CHAPSH3b alone at the same concentration,
according to the unpaired t-test with Welch’s correction. */#p-value < 0.05, **/##p-value < 0.01, ***/###p-value < 0.001 and ****/####p-value
<0.0001.
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CHAPSH3b treatment was noted at the 24-h time point. In fact,
even though the number of cells increased between the 7 h and
24 h time points in samples treated with the phage and protein
combination, viable counts remained much lower than those in
the untreated control (reduction of 2.2 log units). These results
were subsequently confirmed by time-lapse microscopy analysis,
although the action of the lysin stopped at an earlier time point
under these conditions (Fig. 4) (See Supplementary Videos 1 and
2). Thus, when the biofilm was treated with CHAPSH3b alone,
there was a gradual reduction in the number of viable cells up to
5 h post-treatment (Supplementary Video 1). However, after this
time point, there is a gradual increase in bacterial cell coverage
during the remaining incubation time. The results observed during
the initial 5 h of incubation were fairly similar when treatment was
carried out using a combination of the protein and phage
(Supplementary Video 2). By contrast, cell proliferation after this
time point was significantly slowed down by the presence of the
phage. Indeed, the number of cells after 24 h of treatment was
clearly reduced compared to the individual treatment with
CHAPSH3b.
Bacterial killing by CHAPSH3b increases the MOI of phiIPLA-
RODI after three hours of treatment
Next, we sought to explore the mechanism(s) of the synergy
between phage phiIPLA-RODI and CHAPSH3b. One potential
explanation for this phenomenon is that clearance of the
biofilm by the protein might make bacterial cells more
accessible to phage particles. In addition, fast killing by the
protein may lead to an increase in the phage-to-bacteria ratio
(MOI). This would enhance the ability of the virus to exert a
noticeable effect on the bacterial population. To test this
possibility, the MOI in V329 biofilms treated with the phage-
protein combination was compared to that in biofilms treated
with the phage alone (Fig. 5). After 1 h of treatment, the starting
MOI of 30.67 dropped to 11.89 and 0.70 in the phage and
phage-protein treatment, respectively. However, this trend
changed at later time points. Indeed, after 3 h of incubation,
the MOI was consistently higher in the samples treated with
phiIPLA-RODI combined with CHAPSH3b (Fig. 5). The MOI
values after 3, 5, 7, and 24 h of treatment with phage alone
were 1.42, 6.92, 4.78, and 0.46, respectively. In contrast, the
values obtained at the same time points in the wells
corresponding to the combination treatment were 137.55,
74.65, 510.80, and 43.48, respectively.
A similar trend was observed in S. aureus 15981, which forms
strong, polysaccharide-based biofilms. In this strain, however,
CHAPSH3b exerted a faster effect, with a significant reduction in
cell numbers after just 1 h of incubation, and regrowth of protein-
treated samples was slower than in V329 (Supplementary Fig. 1a).
In this case, the MOI values were consistently higher in the
samples treated with the protein-phage combination compared to
those exposed only to the phage at all the analyzed time points.
Indeed, the calculated MOIs after 1, 3, 5, 7, and 24 h of incubation
were 0.001, 0.02, 0.10, 0.12, and 0.06 in samples treated with
phiIPLA-RODI, while the values estimated for the combination
treatment were 0.30, 16.85, 198.47, 46.70, and 33.94 (Supplemen-
tary Fig. 1b).
CHAPSH3b can kill at least 90% of phage-resistant mutants
It is also a possibility that CHAPSH3b may limit phage-resistance
development by killing resistant mutants. To better discern if
this might be the case, ten BIMs of S. aureus V329 with
resistance to phage phiIPLA-RODI were isolated to compare
their CHAPSH3b susceptibility to that of the wild type. This was
Fig. 2 CLSM images of LIVE/DEAD-stained S. aureus V329 24-h-old biofilms after different treatments. Preformed S. aureus V329 biofilms
were treated for 24 h at 37 °C with TSB alone (a and e), 8 µM CHAPSH3b (b and f), 109 PFU/ml of phage phiIPLA-RODI (c and g) or a
combination of 8 µM CHAPSH3b and 109 PFU/ml of phage phiIPLA-RODI (d and h). Green cells were intact cells, whereas eDNA and cells with
compromised cell-envelope integrity were stained in red. Scale bars represent 10 µm.
Fig. 3 Time-kill curve of protein CHAPSH3b and/or phage
phiIPLA-RODI against S. aureus V329 biofilms. 24-h-old biofilms
were treated with protein at 8 µM (gray bars), phage at 1 × 109 PFU/
ml (white bars), or a combination of both (light gray bars) and
incubated for 1, 3, 5, 7, or 24 h at 37 °C. Control wells were treated
with TSB medium alone (black bars). Data correspond to the means
± standard deviations of four independent experiments and
represented in logarithmic scale in colony-forming units per cm2
of biofilm. Bars with an asterisk are statistically different (p < 0.05)
from the untreated control according to the Student’s t-test using
the Holm-Sidak method.
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achieved by determining the specific lytic activity of CHAPSH3b
against the different strains. The specific activity of the chimeric
protein against the wild-type strain S. aureus V329 was
0.051 ΔOD600nm × min
−1 × mg protein−1, with similar results
obtained for seven out of ten BIMs (BIM-2, BIM-4, BIM-6, BIM-7,
BIM-8, BIM-9, and BIM-10) (Table 1). By contrast, the specific
activity displayed by CHAPSH3b in mutants BIM-1, BIM-3, and
BIM-5 was significantly lower (p < 0.05) compared to the wild
type (Table 1). Nonetheless, it must be noted that in BIM-3 and
BIM-5 the protein could still effectively eliminate bacterial cells,
whereas BIM-1 exhibited resistance to CHAPSH3b. Of note,
there was no significant difference in biofilm formation
between the ten BIM strains and the wild-type strain
(Supplementary Fig. 2).
Fig. 4 Time-lapse microscopy of S. aureus V329 biofilms subjected to different treatments. Time-lapse microscopy of 24-h-old S. aureus
V329 biofilms treated with CHAPSH3b (8 µM) (left) or CHAPSH3b (8 µM)+ phage phiIPLA-RODI (109 PFU/ml) (right) during 24 h at 37 °C.
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The combination of CHAPSH3b and phiIPLA-RODI limits
bacterial regrowth in an ex vivo model of wound infection
To evaluate the antibiofilm potential of our compounds on a biotic
surface, we implemented an ex vivo pig skin model of wound
infection. Premature, 3-h-old biofilms established on both intact
and wounded pig skin, were treated with 8 µM CHAPSH3b, phage
phiIPLA-RODI (109 PFU/ml, MOI= 588) or a mixture of both
protein and phage (Fig. 6). Generally speaking, all treatments led
to a significant reduction in the bacterial number after 1 h in intact
skin. However, in wounded skin, this reduction was only
significant for the combination treatment (p ≤ 0.05). Of note,
treatments with CHAPSH3b and a combination of protein and
phiIPLA-RODI resulted in a bacterial reduction of 1.3 and 1.04 log
units, respectively, in the intact skin infection model (Fig. 6a).
These values were almost the same as those observed in the
wound infection model (1 and 1.4 log units, respectively, for the
same treatments) (Fig. 6b). 5-h post-treatment, a significant
difference in bacterial numbers was observed for the treatment
with phiIPLA-RODI (0.8 log units) and the combination of
CHAPSH3b/phiIPLA-RODI (3.3 log units). At the end of the
experiment, all treatments resulted in a reduced number of viable
bacteria compared to the untreated control. In both ex vivo
models, the reduction in bacterial cells after 24 h of treatment was
higher when using phiIPLA-RODI or the combination of phage and
protein (~2.5 log units of reduction). In contrast, treatment with
the protein alone led to final reductions of only ~1 log unit in both
models.
DISCUSSION
Amidst the current antibiotic resistance crisis, bacterial biofilms
pose a particularly dangerous threat. These complex multicellular
structures are, by nature, considerably more resistant to anti-
microbials than their planktonic counterparts. Moreover, when
biofilms are formed by multidrug-resistant bacteria, the chances of
successfully eliminating them are even lower. It is, therefore,
necessary to find alternative strategies that can replace or
complement the currently available antibiofilm agents. In this
context, phage-based antimicrobials are promising candidates.
Bacterial viruses themselves can be used for biofilm removal given
their ability to specifically infect and kill their host, even when
embedded in an extracellular matrix48. However, bacteriophage
treatment is known to select phage-resistant bacteria, even
though such resistant variants are often poor biofilm formers
and/or display growth defects39. Phage-derived lytic proteins can
also be powerful antibiofilm weapons that rapidly lyse their target
cells without the significant selection of resistant variants21. Like
phages, lytic proteins are quite specific and, as a result, harmless
for non-target bacteria and, very importantly, eukaryotic cells.
Moreover, some lytic proteins have been shown to kill persister
cells, a characteristic that is a major asset for an antibiofilm
agent47. Indeed, biofilms usually exhibit a higher proportion of
persister cells than planktonic populations, a characteristic that
boosts their ability to withstand an antimicrobial challenge8. On a
critical note, lytic proteins do not increase in number during
treatment and, depending on the environmental conditions, can
often be unstable and only remain active for a relatively short
time, thus allowing bacterial regrowth or requiring repeated
dosing. This work explores the potential of harnessing the
advantages of both phages and lytic proteins to compensate for
each other’s weaknesses with the aim of developing a more
effective antimicrobial combination.
Previous studies had already shown the ability of phage
phiIPLA-RODI and chimeric protein CHAPSH3b to kill biofilm-
embedded S. aureus cells belonging to certain strains39,46. As a
result, they seemed a good choice to carry out interaction assays
against three S. aureus strains. At the end of the 24-h treatment,
neither antimicrobial was effective for controlling the bacterial
population. In spite of this, exposure to the protein did decrease
the amount of attached biomass in strains 15981 and V329, which
might be due to its biofilm inhibiting properties46. Indeed,
Fernández et al.46 already demonstrated that subinhibitory
concentrations of this protein had a negative impact on biofilm
formation by S. aureus that might be linked to downregulation of
autolysin-encoding genes. The fact that this effect was not
observed in strain IPLA1 might be a consequence of the weak
biofilm formation of this strain in TSB without added glucose. In
contrast to these results, a combination of both antimicrobials had
a much more significant impact on the biofilm population for all
three strains, independently of their susceptibility to phiIPLA-RODI.
In view of these data, it appears that the application of phage
phiIPLA-RODI combined with protein CHAPSH3b would constitute
a viable antibiofilm strategy. Examples of combining these two
phage-based strategies, i.e., phage therapy and lytic proteins, are
scarce. In fact, we are only aware of one study in which a phage-
endolysin combination was tested in a mouse sepsis model
against Acinetobacter baumannii49. In this example, the
Fig. 5 Changes in the MOI during incubation of S. aureus V329
biofilms treated with phage phiIPLA-RODI or a combination of
phage and protein CHAP-SH3b. 24-h-old biofilms were treated with
phage at 1 × 109 PFU/ml (black bars) or a combination of phage at
1 × 109 PFU/ml and protein at 8 µM (gray bars) and incubated for 1,
3, 5, 7, or 24 h at 37 °C. Data correspond to the means ± standard
deviations of three independent experiments and represent the
logarithm of the MOI for each time point. Bars with an asterisk are
statistically different (p < 0.05) from each other according to the
Student’s t-test using the Holm-Sidak method.
Table 1. Specific lytic activity of protein CHAPSH3b against S. aureus
V329 and S. aureus V329-derived BIMs.
Strains Specific lytic activitya
ΔOD600nm ×min−1 ×mg protein−1
V329 0.051 ± 0.004
BIM-1 −0.015 ± 0.010*
BIM-2 0.060 ± 0.023
BIM-3 0.033 ± 0.001*
BIM-4 0.039 ± 0.007
BIM-5 0.028 ± 0.009*
BIM-6 0.054 ± 0.013
BIM-7 0.067 ± 0.027
BIM-8 0.063 ± 0.040
BIM-9 0.073 ± 0.020
BIM-10 0.063 ± 0.011
aValues represent the means ± standard deviations from three indepen-
dent replicates. *indicate values that were statistically different (p < 0.05)
from those of the wild-type strain using an unpaired t-test with Welch’s
correction.
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combination gave similar results to the endolysin alone, although
it is worth mentioning that the authors only tested one
concentration of phage and protein against a single bacterial
strain. With that in mind, it cannot be excluded that different
conditions might have led to the observation of a synergistic
interaction. Nonetheless, it is likely that, as is the case of other
antimicrobials, the existence of synergy will depend on the
specific phage-protein combination and the bacterial strain. There
are several studies reporting the existence of synergy between
either phages or phage lytic proteins with antibiotics36–38,41–43. In
some cases, such combinations were able to reduce the biofilm
population depending on the antibiotic and its concentration.
Nevertheless, there is evidence that antibiotics can also have a
negative impact on phage treatment. This is particularly the case
for drugs that inhibit nucleic acid or protein synthesis, as they
collaterally interfere with phage propagation37. However, this
antagonism depends on the duration of the treatment and the
antibiotic concentration used37,50. Moreover, any strategy invol-
ving conventional antimicrobials has the potential risk of
contributing to the antibiotic resistance problem. These two
important shortcomings of phage/antibiotics combination therapy
would be avoided when combining phages and lytic proteins.
Once ascertained that combining a virulent phage, phiIPLA-
RODI, with CHAPSH3b for biofilm treatment has a positive impact,
we sought to better understand the basis for this interaction. The
results of this analysis suggest that the presence of the phage,
which has no effect by itself, appears to limit the regrowth of the
bacterial population that follows the inactivation of the lytic
protein. On the other hand, the protein, by lysing part of the
bacterial population, increases the phage-to-bacteria ratio,
thereby allowing the phage to exert a significant impact on
biofilm removal. In addition to changing the phage-to-bacteria
ratio, CHAPSH3b might also enhance phage efficacy by killing
potential phage-resistant variants present in the biofilm. Indeed,
our results show that at least 90% of BIMs are susceptible to the
lytic protein. Finally, a third potential contribution of the lytic
protein might be by loosening the biofilm, thus making cells more
accessible to phage infection.
When comparing the different antibiofilm strategies in ex vivo
experiments using the pig skin model, we observed that phiIPLA-
RODI was more effective than CHAPSH3b in limiting the growth of
the bacterial population in the long term. This might be associated
with the fact that porcine skin is a nutrient-rich environment that
favors bacterial growth and, consequently, facilitates phage
propagation. Nonetheless, it must be noted that the combination
treatment generally led to a faster decrease in the short term
compared to the phage alone.
This study shows how we can take advantage of the synergistic
interaction between bacteriophages and lytic proteins to develop
a two-speed antibiofilm cocktail. In this model, the lytic proteins
initiate rapid killing of the microbial community. Once the lysin
activity dwindles, the phage present in the mixture will continue
its antimicrobial action. This slower but longer-term effect limits
regrowth of the target bacterium, thereby facilitating removal by
subsequent treatment. Overall, this strategy provides an interest-
ing antibiotic-free alternative for biofilm elimination with a low
potential for resistance selection.
METHODS
Bacterial strains, lytic proteins, bacteriophages, and growth
conditions
S. aureus strains used in this study included the dairy industry isolate S.
aureus IPLA151, the clinical strain S. aureus 1598152 and the bovine
subclinical mastitis isolate S. aureus V32915. These bacterial strains were
routinely grown at 37 °C in TSB (tryptic soy broth, Scharlau Microbiology,
Barcelona, Spain) by shaking or on plates containing TSB supplemented
with 2% (w/v) agar (Roko, S.A., Llanera, Spain) (TSA). TSB top agar
composed of TSB supplemented with 0.7% (w/v) agar was used for phage
titration. TSB supplemented with 0.25% (v/v) glucose (Merck, Darmstadt,
Germany) (TSBg) was used for biofilm formation assays.
Recombinant protein expression was carried out using Escherichia coli
BL21 carrying the gene coding for CHAPSH3b cloned into plasmid pET21a
as described by35. E. coli was routinely grown in LB medium, supplemented
with 1mM IPTG and 100 μg/ml ampicillin when necessary. The chimeric
protein CHAPSH3b was subsequently purified as described previously35.
Visual analysis and quantification of the concentration of the purified
protein were performed by SDS-PAGE and the quick Start Bradford Protein
Assay Kit (Bio-Rad Laboratories, USA), respectively.
Phage phiIPLA-RODI was routinely propagated on S. aureus IPLA16 and
partially purified by adding 10% polyethylene glycol (PEG) and 0.5 M NaCl
for incubation at 4 °C for 16 h. Concentrated phage was obtained by
centrifugation (10,000 rpm, 30min, 4 °C), resuspended in TSB medium, and
stored at 4 °C until further use.
EOP determination and phage adsorption assays
To determine the EOP of phage phiIPLA-RODI on the different strains, the
phage titer on the test strain was divided by the titer on strain S.
aureus IPLA1.
To estimate the phage adsorption rate, overnight cultures of the
different S. aureus strains were diluted to an OD600 of 1. Next, 900 μl
aliquots from these suspensions (~108 CFU/ml) were mixed with 100 μl of a
phiIPLA-RODI stock leading to a final concentration of 107 PFU/ml (MOI=
0.1). The negative control was prepared by combining 900 μl of non-
inoculated TSB with 100 μl of the phage stock. Phage adsorption was then
allowed to occur for 5 min at room temperature. The samples were
subsequently centrifuged for 3 min at 10,000×g at 4 °C. The number of
Fig. 6 Antibiofilm effect of CHAPSH3b, phiIPLA-RODI or a combination of both on premature biofilms in an ex vivo model of intact and
wounded skin. Antibiofilm effect of CHAPSH3b, phiIPLA-RODI or a combination of both on premature biofilms in an ex vivo model of intact
and wounded skin. A porcine ex vivo model of intact skin (a) and skin wound (b) infection (n= 3) infected with 3-h-old biofilms of S. aureus
V329 (~105 CFU/g skin) was treated with either CHAPSH3b (8 µM), phiIPLA-RODI (MOI of 588) or a combination of both (8 µM and MOI of 588,
respectively). Bars represent the means and standard deviations of three independent experiments. Bars with an asterisk are statistically
different (p < 0.05) from the untreated control according to the Student’s t-test using the Holm-Sidak method.
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non-adsorbed phages was calculated by titrating the resulting super-
natants, and the phage adsorption rate was determined according to the
following equation:
Phage adsorption rate ¼ phage number in supernatant of controlð½ phage number in supernatant sampleÞ
= phagenumber in supernatant of controlð Þ ´ 100
Biofilm formation and treatment
Overnight cultures of each S. aureus strain were diluted 1:100 (v/v) in fresh
TSBg medium. Then, 1 ml of this bacterial suspension was inoculated into
each well of a 24-well polystyrene microtiter plate (Thermo Scientific,
NunclonTM Delta Surface) and the plates were incubated for 24 h at 37 °C.
Afterward, the planktonic phase was removed, and the biofilms were
washed twice with phosphate-buffered saline (PBS; 137mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4, 2 mM KH2PO4 [pH 7.4]). The remaining adhered cells
were then treated with 0.5 ml of TSB medium alone or using the same
medium with different concentrations of protein CHAPSH3b (4–8 µM) and/
or phage phiIPLA-RODI (1 × 109 PFU/ml–1 × 1010 PFU/ml) at 37 °C.
Treatment was allowed to act for 1, 3, 5, 7, or 24 h. Then, the planktonic
phase was removed and the adhered phase was washed twice with PBS.
To assess the efficacy of the different treatments, the number of viable
attached cells and total biomass were quantified. The number of viable
cells present in the biofilms was determined by using the spot test. Briefly,
biofilms were scraped and resuspended in PBS. Afterward, 10 µl droplets
from tenfold serial dilutions of this cell suspension were spotted onto TSA
plates and allowed to dry. These plates were then incubated at 37 °C for
24 h.
The cell counts obtained in these experiments were first used to
determine the number of CFUs per unit area (CFU/cm2) and, subsequently,
the potential interaction between the two antimicrobials (phage and lysin)
as indicated using the following equation53:
log10CFU=cm
2 phageþ lysinð Þ½   log10CFU=cm2 phageð Þ þ log10CFU=cm2 lysinð Þ½ 
(2)
The values obtained with the aforementioned equation were named
interaction indices. The interaction was considered additive when this
index was between −0.5 and 0.5, antagonistic when the value was <−0.5,
and synergistic when the value was >0.5.
Total biomass was quantified by performing the crystal violet staining
assay as described previously47. Briefly, after washing the biofilm with PBS,
1 ml of 0.1% (w/v) crystal violet was added to each well. Fifteen minutes
later, the excess of crystal violet was removed by washing twice with water.
The remaining dye was then solubilized by adding 33% (v/v) acetic acid
and the absorbance at 595 nm (A595) was measured using a Benchmark
Plus Microplate Spectrophotometer (Bio-Rad Laboratories, Hercules,
CA, USA).
To monitor the evolution of the MOI throughout treatment, the number
of viable cells and phage particles was determined in both the planktonic
phase and the biofilm. Next, the values obtained for both phases were
added to calculate the total number of infective phage particles and
bacterial cells, and the ratio between the two populations was calculated
to determine the MOI by dividing the number of PFUs by the number
of CFUs.
Determination of minimum inhibitory concentrations (MICs)
The MICs of the protein and the phage were determined using the broth
microdilution technique in TSB medium with some modifications54. Thus,
in the case of the phage, tenfold dilutions of the viral suspension were
assayed instead of the usual twofold dilutions. The MIC was defined as the
lowest concentration that inhibited visible bacterial growth after 24 h of
incubation at 37 °C. The experiment was performed in triplicate and the
MIC was expressed as the mode of three independent replicates.
Isolation of bacteriophage insensitive mutants (BIMs)
BIMs of S. aureus V329 were isolated as described previously39. Briefly,
100 µl from an overnight culture were mixed with 100 µl of phage (5 × 109
PFU/ml), spotted onto the center of a 2% TSA plate and covered with 0.7%
TSA. Afterward, the plates were incubated for 24 h at 37 °C. Some of the
surviving colonies were picked with a pipette tip and grown in fresh TSB
medium for 16 h at 37 °C. The insensitive phenotype of the selected
colonies was then confirmed by using the spot assay.
Quantification of the CHAPSH3b specific lytic activity
Overnight cultures of S. aureus V329 and the ten isolated BIM strains were
grown at 37 °C with shaking and then the turbidity reduction assay was
performed as described previously with some modifications55. Briefly, after
reaching an OD600 of 0.5–0.6, the bacterial cells were washed and then
resuspended in NaPi buffer (50mM, pH 7.4) at a final OD600 ~1.0. Next, the
freshly prepared cell suspensions were treated with two-fold dilutions of
purified CHAPSH3b (0.027–1.720mg/ml). The specific lytic activity of the
protein was expressed in OD600nm ×min
−1 ×mg protein−1 56.
Analysis by CLSM and time-lapse microscopy
Confocal and time-lapse microscopy were performed as described
previously, with some modifications46. For confocal microscopy analysis,
24-h-old biofilms were formed by inoculating 2ml of an S. aureus V329 cell
suspension containing approximately 106 CFU/ml in TSBg in two-well µ-
slides with a glass-bottom (ibidi, Martinsried, Germany), and subsequent
incubation under static conditions at 37 °C. After growth, the planktonic
phase was removed and the biofilm was washed twice with PBS. Then, TSB
medium alone or containing phage phiIPLA-RODI (5 × 109 PFU/ml), protein
CHAPSH3b (8 µM), or both together were added to the biofilm and
incubated for 24 h at 37 °C. At the end of the treatment, wells were washed
twice with PBS and stained with the Live/Dead® BacLightTM kit (Invitrogen
AG, Basel, Switzerland). Samples were observed under a confocal scanning
laser microscope (DMi8, Leica Microsystems) using a 63 × oil objective.
For time-lapse microscopy, 24-h-old biofilms were grown at 37 °C and
then washed twice with PBS. Next, different treatments were added to the
biofilm: TSB containing protein CHAPSH3b (8 µM) or phage phiIPLA-RODI
(5 × 109 PFU/ml) combined with protein CHAPSH3b. Then the plate was
placed in an incubation chamber, set at 37 °C, and connected to an
inverted microscope (DMi8; Leica Microsystems) equipped with a Leica
DFC365FX digital camera. Images were acquired every 15min using LasX
software (Leica Microsystems) for approximately 24 h.
Ex vivo pig skin model of wound infection and treatment
To assess the antibiofilm effect of CHAPSH3b and phiIPLA-RODI on a biotic
surface, a previously described pig skin model was used with minor
adaptions57. Pig skin was obtained from the Minimally Invasive Surgery
Center Jesús Usón (Cáceres, Spain). First, the upper layer was disinfected
with 70% ethanol. This disinfection was repeated after removing residual
hair. Next, the skin was cut in 1 × 1 cm explants. To mimic a wound
phenotype, a wound bed of 48mm diameter and 1mm depth was made
using a hand drill with a cutter bit (Dremel® #192) in specific explants.
Next, all the explants, with or without a wound, were submerged in 70%
ethanol for 1 h followed by 30min of UV decontamination to ensure
complete sterility. Two different experimental setups were carried out in
parallel, for explants with and without a wound. For each time point, three
explants without a wound and three explants with a wound were placed in
24-well plates containing 1ml physiological saline agar (0.9% (w/v) NaCl,
0.5% (w/v) agar, pH 5.5) to mimic human skin conditions. The explants
were inoculated with S. aureus V329 (105 CFU/g of skin) and incubated at
37 °C (5% CO2) for 3 h to allow for biofilm formation. Then, the explants
were treated with 100 µl CHAPSH3b (8 µM), phiIPLA-RODI (MOI= 588), or
100 µl of a mixture containing CHAPSH3b (8 µM) and phiIPLA-RODI (MOI=
588). Treatment with 100 µl of TSB was used as a negative control. Explants
were processed after 0, 1, 5, and 24-h of treatment (37 °C, 5% CO2). After
incubation, bacteria were recovered by inserting the explant in a
stomacher bag (BagPage, BagSystem, Interscience, St-Nom-la-Breteche,
France) containing 5 ml of PBS and homogenized using a stomacher for
2 × 90 s (model 80, Seward Medical, London, UK). From this, a tenfold
dilution series was made in PBS, and colony-forming units (CFUs) were
determined by plating duplicates on Baird-Parker agar plates that were
incubated for 16-h at 37 °C.
Statistical analysis
Statistical analysis of the biofilm data was carried out by multiple t-tests,
using the Holm-Sidak method or Welch’s correction using GraphPad Prism
6 software. P-values lower than 0.05 were considered significant.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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